MNG484
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.427
- HEDGEHOG_SIGNALING+0.405
- APICAL_SURFACE+0.393
- ANGIOGENESIS+0.385
- OXIDATIVE_PHOSPHORYLATION+0.324
- APICAL_JUNCTION+0.292
- PROTEIN_SECRETION+0.286
- MYOGENESIS+0.283
- UV_RESPONSE_DN+0.269
- FATTY_ACID_METABOLISM+0.245
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.323
- ALLOGRAFT_REJECTION-0.262
- E2F_TARGETS-0.208
- MYC_TARGETS_V2-0.196
- MYC_TARGETS_V1-0.177
- SPERMATOGENESIS-0.164
- PI3K_AKT_MTOR_SIGNALING-0.154
- IL6_JAK_STAT3_SIGNALING-0.147
- APOPTOSIS-0.143
- G2M_CHECKPOINT-0.095
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0H7-01A-13R-A056-07 | — | B | 0.697 |
| 2 | e2ac493b-9157-4756-8949-edf4b7f334cd | — | — | 0.672 |
| 3 | AUR-AER6-TTM6-A-1-1-R-A742-41 | — | C | 0.663 |
| 4 | TCGA-CR-7401-01A-11R-2016-07 | — | — | 0.648 |
| 5 | 4df6c488-ef2f-4019-a1b0-3a3624039be8 | — | — | 0.633 |
| 6 | TCGA-44-8120-01A-11R-2241-07 | — | cohortA1 | 0.612 |
| 7 | TCGA-56-7822-01A-11R-2125-07 | — | cohortSQ1 | 0.612 |
| 8 | SRR8942951 | — | — | 0.603 |
| 9 | TCGA-A8-A09D-01A-11R-A00Z-07 | — | A | 0.599 |
| 10 | 5b6bd2fd-de8e-4d58-9b38-c3b2bf2ed418 | — | — | 0.596 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.427 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.405 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.393 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.385 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.324 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.292 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.286 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.283 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.269 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.245 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.235 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.224 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.215 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.211 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.209 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.161 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.136 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.115 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.092 | Inavolisib | — uncovered |
| COAGULATION | 0.084 | Binimetinib | — uncovered |